C3P-No! USPTO Says No AI Inventors
Client Alert | 1 min read | 05.04.20
Last Monday, the PTO affirmed its earlier (and unsurprising) position that a patent application filed in July was incomplete because it named an artificial intelligence as the inventor. The application is believed to be among the first to name an AI as an inventor.
In reaffirming its position of AI non-inventorship, the PTO noted that the Title 35 consistently suggests personhood and refers to inventors as natural persons. As one example, said the PTO, the statutes involving the inventor oath or declaration refer to the executor as a “person.” Interpreting “inventor” to broadly encompass non-persons, argued the PTO, would contradict the plain reading of the statutes.
The USPTO also relied on Federal Circuit decisions that exclude states and corporations from holding inventorship. These decisions, the PTO noted, explain that the entire concept of “conception” – the touchstone of inventorship – requires a human mind to do the conceiving.
The attempt to name an AI as the inventor illustrates how advances in AI technology continue to challenge our traditional thinking about personhood – and how the law will have to cope with the evolving concept. Read the full decision here.
Contacts
Insights
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
The U.S. Government Accountability Office’s (GAO) recent decision in Viderity Inc.—Costs, B-424422.5, Sept. 1, 2026, offers useful insight into what constitutes a legally sufficient conflict of interest investigation. The decision arose in an unusual procedural posture: Viderity initially protested, alleging that an agency evaluator had a personal conflict of interest. After the agency took corrective action, Viderity filed a cost entitlement claim requesting that GAO direct the agency to reimburse Viderity’s protest costs. In evaluating that claim, GAO assessed whether Viderity’s underlying protest ground was “clearly meritorious.”
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance



